证券代码：300314 证券简称：戴维医疗 公告编号：2024-040 宁波戴维医疗器械股份有限公司 关于股东签署一致行动协议书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"或"戴维医 疗"）原控股股东、实际控制人之一陈云勤先生于2024年9月逝世。公 司控股股东、实际控制人之一陈再宏先生通过继承方式，依法取得陈 云勤先生生前持有的公司股份。为稳固公司的控制权并保持公司平稳 有序发展，陈再宏先生与公司控股股东、实际控制人之一陈再慰先生 就一致行动相关事宜签署了《一致行动协议书》，具体情况如下： （1）本协议签订时签约双方持有的戴维医疗的股份； 1、一致行动的有效期 自本协议签署之日起至2027年10月16日止。在本协议期满前一个 月，经双方一致同意，可以延长本协议的有效期。 2、一致行动股份 签约双方确认并同意，本协议所称的一致行动股份指签约双方所 持有的戴维医疗的全部股份，包括： （2）本协议签订后，签约双方因获送红股、受让、获赠、获授予 或者其它原因增加持有的戴维医疗的股份； （3）因股权激励，签约双 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2024-039 宁波戴维医疗器械股份有限公司关于 公司控股股东、实际控制人变更暨权益变动 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 （一）信息披露义务人及其一致行动人基本情况 1、信息披露义务人 姓名：陈再宏 性别：男 身份证号码：3302251969******** 特别提示: 1、本次权益变动系公司原控股股东、实际控制人之一陈云勤先生逝世产生 的遗产继承所致，陈再宏先生通过继承方式获得公司股份，上述股份继承事项不 会对公司产生重大不利影响。 2、本次权益变动后，公司的共同控股股东、实际控制人由陈再宏先生、陈 云勤先生、陈再慰先生变更为陈再宏先生、陈再慰先生。 3、本次权益变动不触及要约收购。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于近日收 到公司控股股东、实际控制人陈再宏先生和陈再慰先生出具的《宁波 戴维医疗器械股份有限公司详式权益变动报告书》（以下简称"《详 式权益变动报告书》"），现将相关情况公告如下： 一、本次权益变动基本情况 国籍：中国 通讯地址：浙江省宁波市象山 ...

宁波戴维医疗器械股份有限公司 详式权益变动报告书 上市公司名称：宁波戴维医疗器械股份有限公司 信息披露义务人：陈再宏 住所及通讯地址：浙江省宁波市象山县石浦科技园区科苑路 2 号 信息披露义务人的一致行动人：陈再慰 住所及通讯地址：浙江省宁波市象山县石浦科技园区科苑路 2 号 1 上市地点：深圳证券交易所 股票简称：戴维医疗 股票代码：300314 股权变动性质：继承 信息披露义务人及其一致行动人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有 相同含义。 一、本报告书系依据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披 露内容与格式准则第 15 号——权益变动报告书》及相关法律、法规 和规范性文件编写。 二、信息披露义务人签署本报告书无需获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变 动报告书》及相关法律、法规和规范性文件的规定，本报告书已全面 披露信息披露义务人及其一致行动人在宁波戴维医疗器械股份有限 公司中拥有权益的股份。 截至本报告书签 ...

| 上黏膜选择性切除用。 | | --- | 证券代码：300314 证券简称：戴维医疗 公告编号：2024-038 宁波戴维医疗器械股份有限公司 关于全资子公司部分医疗器械产品完成延续注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司 宁波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日取得 由浙江省药品监督管理局颁发的4项《医疗器械注册证》，维尔凯迪产品 一次性使用直线型切割吻合器及组件、一次性使用直线型吻合器及组件、 一次性使用管型吻合器、一次性使用肛肠吻合器等完成了延续注册，具 | 体如下： | | --- | | 序号 | 产品名称 | 注册证编号 | | | | 注册证有效期至 | 注册分类 | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一次性使用直 | 浙 | 械 | 注 | 准 | 2030.04.25 | Ⅱ类 | 产品适用于消化道重建、 | | | 线型切割吻合 | 201 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2024-037 宁波戴维医疗器械股份有限公司 关于新产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、医疗器械注册证的具体情况 产品名称：医用加热仪 型号、规格：T-100、T-100A、T-100B、T-100C 注册证编号：浙械注准20242091822 批准日期：2024年09月27日 有效期至：2029年09月26日 注册分类：Ⅱ类 适用范围：产品适用于医疗机构对患者（小于等于10Kg）进行物 理升温、保持体温。 近日，宁波戴维医疗器械股份有限公司（以下简称"公司"）的 新产品医用加热仪获得了浙江省药品监督管理局颁发的《医疗器械注 册证》，具体如下： 三、对公司的影响 以上产品医疗器械注册证的取得，有利于丰富公司产品线，进一 步提高公司的核心竞争力，对公司未来的经营成果将产生积极影响。 四、风险提示 目前尚无法预测该等产品对公司未来营业收入的影响，敬请投资 者注意投资风险。 特此公告。 宁波戴维医疗器械股份有限公司 董事会 2024年10月09日 二、新产品的市场状 ...

证券代码：300314 证券简称：戴维医疗 公告编号：2024-036 宁波戴维医疗器械股份有限公司 关于公司控股股东、实际控制人之一陈云勤先生逝世 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）董事会沉 痛公告，公司收到公司创始人、控股股东、实际控制人之一陈云勤先 生的家属通知，陈云勤先生因病医治无效，于2024年9月20日与世长 辞，享年82岁。 陈云勤先生作为公司的创始人，在党和政府的领导下，始终坚持 "创新领先、保质求量、勤俭创业、和谐发展"的经营理念，带领公 司广大员工勇于探索、艰苦创业、呕心沥血、开拓创新，并在不同时 期总能根据变化了的形势，深谋远虑、高瞻远瞩，对公司的战略作出 正确决策，使公司逐步发展壮大。 公司董事、监事、高级管理人员及全体员工对陈云勤先生的辛勤 付出和卓越贡献怀有崇高的敬意与无尽的感激，对陈云勤先生的逝世 表示沉痛哀悼和深切缅怀，并向其家人致以深切慰问！ 宁波戴维医疗器械股份有限公司 董事会 2024年9月23日 陈云勤先生目前持有公司股份60,820,000股，占公司 ...

与会监事一致认为：公司《2024年半年度报告全文》及《2024年 半年度报告摘要》的编制和审核程序符合法律、行政法规和中国证监 会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不 存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司在中国证监会指定的创业板信息披露网站上 披露的相关公告。 本议案以 3票同意，0票反对，0票弃权获得通过。 二、备查文件 证券代码：300314 证券简称：戴维医疗 公告编号：2024-035 宁波戴维医疗器械股份有限公司 第五届监事会第九次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届监 事会第九次会议于2024年08月19日上午在公司会议室以现场方式召 开。本次会议于2024年08月09日以专人送达形式通知了全体监事。本 次会议应参与表决的监事3名，实际参与表决的监事3名。本次会议的 通知、召开以及参会监事人数均符合相关法律、法规、规则及《公司 章程》的有关规定。本次会议由监事会主席陈红主持，出席本次会议 的全体监事对本次会议的议案进行了认 ...

Financial Performance - The company's revenue for the first half of 2024 reached RMB 1.2 billion, representing a year-on-year growth of 15%[2] - Net profit for the first half of 2024 was RMB 250 million, an increase of 20% compared to the same period last year[2] - Revenue for the reporting period decreased by 16.23% to RMB 265,824,458.42 compared to the same period last year[12] - Net profit attributable to shareholders of the listed company decreased by 49.31% to RMB 46,526,145.36[12] - Revenue for the first half of 2024 was RMB 265,824,458.42, a decrease from RMB 317,308,737.59 in the same period last year[141] - Operating profit for the first half of 2024 was RMB 52,899,639.08, down from RMB 104,026,095.13 in the same period last year[141] - Net profit for the first half of 2024 was RMB 46,526,145.36, compared to RMB 91,776,799.20 in the same period last year[142] - Revenue from the parent company for the first half of 2024 was RMB 178,207,830.50, a decrease from RMB 193,772,538.38 in the same period last year[144] - Net profit from the parent company for the first half of 2024 was RMB 26,077,431.85, compared to RMB 58,168,220.49 in the same period last year[144] - Sales revenue from goods and services in 2024 H1 decreased to 262,692,397.67 yuan from 330,715,136.99 yuan in 2023 H1, a decline of approximately 20.6%[146] - Parent company's sales revenue from goods and services in 2024 H1 was 166,331,471.33 yuan, a decrease from 199,445,744.44 yuan in 2023 H1[149] Profit Margins and Costs - The company's gross profit margin improved to 45%, up from 42% in the previous year[2] - Research and development expenses accounted for 8% of total revenue, amounting to RMB 96 million[2] - The gross profit margin for obstetric and pediatric care equipment was 54.13%, an increase of 3.52% compared to the same period last year[73] - The gross profit margin for minimally invasive surgical instruments was 65.93%, a decrease of 5.00% compared to the same period last year[73] - R&D expenses increased to RMB 25,011,237.72 in the first half of 2024, up from RMB 17,114,449.96 in the same period last year[141] - Sales expenses for the first half of 2024 were RMB 52,683,236.40, a decrease from RMB 63,870,825.74 in the same period last year[141] Cash Flow and Financial Position - The company's cash and cash equivalents stood at RMB 500 million as of June 30, 2024[2] - Net cash flow from operating activities decreased by 98.03% to RMB 784,617.96[12] - The company's total assets increased by 8% to RMB 3.5 billion compared to the end of 2023[2] - The company's debt-to-equity ratio improved to 0.5, down from 0.6 at the end of 2023[2] - Total assets decreased by 1.13% to RMB 1,358,533,212.66 compared to the end of the previous year[12] - Net cash flow from operating activities in 2024 H1 dropped significantly to 784,617.96 yuan compared to 39,851,190.29 yuan in 2023 H1[146] - Net cash flow from investing activities in 2024 H1 was -234,850,563.14 yuan, a sharp decline from 49,383,134.75 yuan in 2023 H1[148] - Net cash flow from financing activities in 2024 H1 was -21,037,798.08 yuan, an improvement from -45,092,548.04 yuan in 2023 H1[148] - Total cash and cash equivalents at the end of 2024 H1 stood at 302,590,835.68 yuan, down from 440,729,166.75 yuan at the end of 2023 H1[148] - Parent company's net cash flow from operating activities in 2024 H1 was -18,499,739.01 yuan, compared to 19,836,271.88 yuan in 2023 H1[149] - Parent company's total cash and cash equivalents at the end of 2024 H1 were 246,104,332.57 yuan, down from 369,696,809.22 yuan at the end of 2023 H1[150] International Expansion and Market Presence - The company's subsidiary, David Medical Europe, contributed 12% to total revenue, generating RMB 144 million[5] - The company plans to expand its market presence in Europe and North America, targeting a 10% increase in international sales by the end of 2024[2] - The company has entered over 600 top-tier hospitals in China and has agents in more than 30 provinces, serving over 140 countries and regions globally[18] - The company's products have entered over 300 top-tier hospitals in China and have been registered and sold in multiple countries across Asia, Europe, the Americas, the Middle East, and Africa[20] - Overseas business revenue reached 105.4932 million yuan, a year-on-year increase of 6.97%[29] - The company's products are sold in over 140 countries and regions globally, with significant market share growth[28] - The company has entered markets in Asia, Europe, the Americas, the Middle East, and Africa, covering over 80 countries and regions[28] - The Portugal-based subsidiary, Davie Europe, is advancing preparations for its production base, which will serve as a global R&D, production, sales, and service platform[29] - The company has completed new product registrations and approvals in multiple countries and regions, ensuring compliance with local regulations[29] - Overseas revenue for pediatric care equipment reached 74.85 million USD, a year-on-year increase of 8.59%[36] - Overseas revenue for minimally invasive surgical instruments reached 29.97 million USD, a year-on-year increase of 5.62%[36] Product Development and Innovation - New product launches, including advanced neonatal care equipment, are expected to contribute 15% to total revenue in the next fiscal year[2] - The company is developing a dual-light path transcutaneous jaundice meter to improve measurement accuracy and adaptability for different patient groups, with added wireless data transmission technology for easier record-keeping by medical staff[18] - The company has 6 electric stapler registrations, including 2 "Class III" management categories, expanding indications to more organs and tissues[20] - The company launched China's first disposable electric cutting stapler for endoscopic use in 2018 and the world's first intelligent fully automatic turning stapler in 2022[20] - The company is accelerating the launch of emergency surgery ICU products, including an emergency integrated machine, emergency ventilator, emergency stretcher, and operating table[21] - The company invested 25.01 million yuan in R&D during the reporting period, accounting for 9.41% of operating revenue[22] - The company holds 239 patents, including 55 invention patents, 136 utility model patents, 48 design patents, and 3 software copyrights[22] - The company's products have reached the third generation, with some products and R&D projects achieving fourth-generation levels[22] - The company is a national high-tech enterprise in the pediatric and obstetric care equipment sector, with leading or pioneering technologies in China[22] - The company has obtained 6 electric stapler registration certificates, including the first domestic third-generation electric cutting stapler for single-use endoscopic use and the world's first electric turning stapler for single-use endoscopic linear cutting[23] - The company submitted 11 patent applications and obtained 5 new patents in the field of pediatric and obstetric care equipment, including 2 invention patents and 3 utility model patents, bringing the total number of valid patents to 196[23] - In the field of minimally invasive surgical instruments, the company launched new products such as single-use electric anorectal staplers and single-use anorectal ligation devices, and submitted 8 patent applications, obtaining 1 new design patent, with a total of 43 valid patents[23] - The company's infant incubator environmental control technology uses a unique feedforward decoupling algorithm and adaptive algorithm to ensure stable and precise control, shortening the R&D cycle and enabling rapid product iteration[24] - The infant incubator noise reduction technology features an optimized finite element air duct structure and air circulation system, ensuring an extremely low noise environment for newborns[24] - The multifunctional integration technology allows the integration of various medical devices and functions into the incubator, such as ECG monitoring, oxygen saturation monitoring, temperature control, and jaundice treatment, reducing hospital costs and enhancing market adaptability[24] - The company's electric stapler technology enables one-handed operation with a 60° large turning angle, improving surgical efficiency and providing uniform cutting and stapling effects, along with a unique "waterdrop-shaped" anvil design for better hemostasis[25] - The company's core pediatric and obstetric care products include infant incubators, infant radiant warmers, neonatal jaundice treatment devices, and jaundice detection devices, with new models such as the YP-2200, YP-2800, and YP-3100 series incubators[26] - The company's minimally invasive surgical instruments, particularly the endoscopic stapler series, have entered international markets in Asia, Europe, the Americas, the Middle East, and Africa, driven by increasing demand for stable and convenient surgical operations[26] - The high-end infant incubator series integrates functions such as monitoring, resuscitation, and treatment, with advanced features like PID core algorithm upgrades, stable temperature control, and a 360° rotating infant bed for comprehensive neonatal care[26] - The company has developed a 360° blue light irradiation system for neonatal jaundice treatment, enhancing treatment effectiveness[27] - The third-generation electric endoscopic stapler features advanced functions such as electric firing, intelligent compression, and 360° rotation, improving surgical safety and efficiency[27] - The company has introduced a "mother-infant co-room" mode, supporting kangaroo care to promote the growth and development of premature and low-weight infants[27] - The company collaborates with hospitals and universities, including Ningbo First Hospital and Ningbo University, on high-frequency ventilator projects[30] - The company actively participates in international exhibitions and customer visits, enhancing brand influence and opening new markets[29] - The company is accelerating its globalization strategy, focusing on pediatric care equipment and minimally invasive surgical instruments[36] - The company is continuously optimizing its product structure and increasing the proportion of high-value-added products[37] - The company is a leading domestic manufacturer of neonatal care equipment, with products such as infant incubators, radiant warmers, and jaundice treatment devices, achieving third-generation technology levels and some fourth-generation advancements[47] - The company holds certifications such as CMDC and CE, with several technologies being domestically leading or pioneering, including "Infant Incubator Environmental Control Technology" and "Low Noise Technology for Infant Incubators"[47] - The company's minimally invasive surgical instruments include electric endoscopic staplers, manual endoscopic staplers, and open series staplers, which are widely used in various surgical fields such as gastrointestinal, hepatobiliary, and gynecological surgeries[48][49] - The third-generation electric staplers developed by the company have shown a nearly 50% reduction in bleeding complications compared to manual staplers, improving surgical precision and patient recovery[49] - The company's one-time endoscopic electric cutting stapler is the first domestically certified third-generation stapler in China, positioning it as a leader in the domestic market[50] - The global market for emergency surgery and ICU products is expanding, driven by aging populations, rising chronic diseases, and increased demand for advanced medical equipment[51] - In China, ICU bed capacity is required to reach 10% of total hospital beds, as per the 2022 national policy, accelerating the demand for ICU equipment[51] - The company is actively developing emergency surgery and ICU products, including emergency integrated machines, ventilators, stretchers, and surgical beds, leveraging its R&D and sales resources[52] - The domestic market for emergency surgery and ICU products is highly competitive, with major players like Mindray, Philips, GE, and Medtronic dominating the sector[52] - The company is focusing on enhancing its product portfolio in pediatric and obstetric care equipment while expanding its presence in minimally invasive surgical instruments and emergency surgery ICU products[52] - The aging population and increasing surgical demand, particularly for minimally invasive procedures, are driving the growth of the stapler market, with the elderly population requiring twice as many surgeries as other age groups[49] - The company is benefiting from the trend of domestic substitution in the stapler market, supported by improved product capabilities, mature market investments, and centralized procurement policies[50] - The company and its subsidiaries currently hold a total of 72 medical device registration certificates, an increase of 6 from 66 in the same period last year[53] - There are 13 medical device registration certificates currently under application[53] - The company's medical device registration certificates are all valid, with expiration dates ranging from 2027 to 2029[53][54] - The company has multiple models of infant incubators registered, including YP-100, YP-100A, YP-90, YP-910, YP-2000, and YP-3000 series[53][54] - The infant incubators have various clinical applications, including growth support for premature infants, phototherapy for neonatal hyperbilirubinemia, and non-invasive measurement of SpO2 and pulse rate[53][54] - The company has registered infant transport incubators (TI-2100A, TI-3000A series) for safe transportation of low-weight and critically ill infants[54] - The company has registered infant radiant warmers (HKN-90, HKN-500 series) for neonatal care and temperature regulation[54] - Some models of infant incubators and radiant warmers are equipped with additional monitoring functions, including ECG, non-invasive blood pressure, and end-tidal CO2 monitoring[54] - The company's medical devices are classified as Class III medical devices according to Chinese regulations[53][54] - All registered medical devices are owned by the company and its subsidiaries[53][54] - The company's infant radiant warmer (HKN-93A, HKN-93B) includes integrated jaundice treatment, while HKN-93C and HKN-93CS models also feature positive pressure ventilation resuscitation, negative pressure suction, air-oxygen mixing, and pulse oximetry monitoring functions[10] - The HKN-2000 infant radiant warmer maintains thermal balance for neonatal patients through infrared radiation and is used for open care or resuscitation[11] - The HKN-2001 and HKN-2001L infant radiant warmers provide thermal balance for newborns and infants, with integrated jaundice treatment and optional resuscitation and monitoring systems[12] - The infant T-combination resuscitator is designed for respiratory emergency care in neonatal intensive care units, supporting infants weighing up to 10kg[13] - The neonatal jaundice treatment box (model: 20182090033) uses visible light (400nm-550nm) to reduce bilirubin levels in newborns[15] - The neonatal jaundice treatment bed (model: 20142090001) also utilizes visible light (400nm-550nm) for bilirubin reduction in newborns[18] - The medical air-oxygen mixer (model: 20182080047) regulates oxygen concentration and flow, with optional humidification capabilities[20] - The neonatal specialized monitor (model: 20212070101) tracks ECG, non-invasive blood pressure, SpO2, pulse, temperature, respiration, CO2, hemoglobin, and environmental oxygen levels[28] - The multi-parameter monitor (model: 20212070235) is used for monitoring ECG, heart rate, respiration, SpO2, and other vital signs in medical settings[29] - The company's infant T-combination resuscitator is expected to be used in medical institutions for resuscitation of infants weighing no more than 10kg, with a validity period until September 17, 2026[30] - The brain monitor and hypothermia therapy device are used for monitoring brain signals and physiological parameters, with a validity period until May 29, 2027[31] - The portable suction device is designed for medical institutions to extract secretions and fluids, with a validity period until May 31, 2027 and October 18, 2027[32][33] - The medical infant bed and infant head fixation frame are used for neonatal care and surgical support, with no specified validity period[34][35] - The manual cart and emergency stretcher are used for patient transport, with no specified validity period[38][40] - The medical isolation pads are used for general patient protection during treatment, with no specified validity period[39][41][42] - The disposable tubular stapler is used for digestive tract reconstruction surgeries, with a validity period until April 25, 2025[44] - The disposable linear stapler is used for digestive tract reconstruction and organ resection surgeries, with a validity period until April 25, 2025[45] - The company has a range of medical devices under the "Weilkadi" brand, including linear cutting staplers, laparoscopic instruments, and infant resuscitation equipment, with various registration and expiration dates ranging from 2025 to 2029[46-59] - The "Disposable Electric Laparoscopic Linear Cutting Stapler" is classified as a Class III medical device, suitable for use in hospitals for procedures involving the stomach, intestines, lungs, liver, gallbladder, pancreas, spleen, and kidneys[55] - Several products, such as the "Disposable Linear Cutting Stapler and Cartridge" and the "Disposable Umbilical Cord Cutter," are undergoing renewal registration, indicating ongoing compliance and market availability[53][54] - The "Disposable Laparoscopic Linear Cutting Stapler" and its components are designed for use in both open and minimally invasive surgeries across various medical specialties, including general surgery, gynecology, urology, thoracic surgery, and pediatrics[58][59] - The company has 33 R&D projects in progress, including various medical devices such as infant respiratory systems, heated breathing tubes, and surgical instruments[61] - The company is developing a neonatal transport incubator (TI5000A) that provides a controlled environment for premature and newborn infants during transport and MRI examinations, with SpO2 and PR monitoring capabilities[60] - A new registration for a disposable electric anorectal stapler is underway, designed for selective

2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | 资金占用 | 占用方与上 | 上市公司核算 | 2024 年期初 | 2024 年 占用累计发生 | 1-6 月 | 2024 年 | 1-6 月 | 2024年1-6月 | 2024年6月末 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 方名称 | 市公司的关 | 的会计科目 | 占用资金余 | 金额（不含利 | | 占用资金的利 | | 偿还累计发 | 占用资金余 | 成原因 | 占用性质 | | | | 联关系 | | 额 | | | 息（如有） | | 生金额 | 额 | | | | | | | | | 息） | | | | | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | | ...

《2024年半年度报告全文》和《2024年半年度报告摘要》详细内容见 公司在中国证监会指定的创业板信息披露网站上披露的相关公告。 本议案已经公司第五届董事会审计委员会第九次会议审议通过。 本议案以9票同意、0票反对、0票弃权的表决结果获得通过。 证券代码：300314 证券简称：戴维医疗 公告编号：2024-034 宁波戴维医疗器械股份有限公司 第五届董事会第九次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）第五届董事会 第九次会议于2024年08月19日上午在公司会议室以现场表决的方式召开。 应参加表决董事9人，实际参加表决董事9人，符合《公司法》和《公司章 程》等相关法律法规的有关规定。本次董事会会议通知已于2024年08月09 日以专人送达、电话方式通知全体董事。董事长陈再宏先生召集和主持了 本次会议，公司监事、高管列席了会议。本次会议以记名投票的表决方式 表决通过了以下决议： 一、审议通过《关于公司 2024 年半年度报告全文及摘要的议案》 董事会认为：公司《2024年半年度报告全文》及 ...